Jonni Moore, Ph.D., Scientific Advisory Board Chair
Dr. Moore is a Professor in the Department of Pathology and Laboratory Medicine, Director of Flow Cytometry Laboratory at the Hospital of the University of Pennsylvania (HUP), Director of the Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory, and Director of Path BioResource, the infrastructure for proteomic, genomic and cytometric resource labs in the Department of Pathology and Laboratory Medicine. She obtained her doctoral degree in Microbiology from Thomas Jefferson University and pursued postdoctoral training in the Immunology Graduate Group at the University of Pennsylvania School of Medicine. Dr. Moore was recruited to the University of Pennsylvania faculty in Pathology and Laboratory Medicine in 1991. In 1996, Dr. Moore was selected as the inaugural director of Clinical Flow Cytometry and has served as the Director of the Clinical and Research Flow Cytometry at HUP. The laboratory was one of the first nationally to implement advanced 4 color immunophenotyping, in place now over 5 years, and will continue to provide leading diagnostic technology by implementing 6 color immunophenotyping utilizing cutting edge cytomic analyses. Recognized regionally as a major referral site for clinical and translational studies involving flow cytometry, Dr. Moore and the laboratory are sought for their expertise in cytomic testing both regionally and nationally. Dr. Moore has a national reputation as one of the leaders in the area of flow cytometry. She has served as Director of the Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource since 1991 and has led the establishment of the laboratory as one of the leading academic resource laboratories in the US. She is active in both the International Society of Analytical Cytology and in the Clinical Cytometry Society. She also serves as external advisor to the Institute for Human Cell Therapy at the Center for Blood Research at Harvard School of Medicine. Dr. Moore is a frequent invited speaker on applications of cytomic technology to clinical testing and serves as a reviewer for several journals including Cytometry and Journal of Immunology.

Michael Pellini, Board of Directors
Mike Pellini teamed up with two biotechnology leaders, Michael Wall, an early industry pioneer at Centocor, Inc., and Richard Pops, the CEO of Alkermes, Inc., a premiere Boston-based biopharmaceutical company, when their company, Genomics Collaborative, Inc. (GCI), was in existence less than a year. Dr. Pellini originally served as a consultant to GCI for six months, joining full time as Vice President of Business Development in July 1999. Appointed Chief Executive Officer in June of 2000, Dr. Pellini spearheaded the development of multiple alliances with Pharmaceutical and Biotech Companies, leading academic and government institutions, and international research centers. Prior to joining GCI, Dr. Pellini trained as a physician within the Thomas Jefferson University Health System (Philadelphia). Before attending medical school, Dr. Pellini worked for several years in the Institutional investment group at Merrill Lynch and led a group of investment managers in Sydney, Australia, where he was named the Company's "Executive of the Year" for the establishment of a new national standard for asset growth in 1989. His professional activities include working closely with the Executive Committee and Alumni Committees of Thomas Jefferson University Medical College as well as the Biotech Committee of Boston College. Dr. Pellini received a B.A. from Boston College, his M.B.A. from Drexel University, and his M.D. from Thomas Jefferson University Medical College.

Stephen M. Goodman, Legal Council, Corporate Affairs
Steve Goodman is a partner in the law firm Morgan, Lewis & Bockius, LLP  in the Business and Finance Practice. Mr. Goodman is co-chairman of the firm's Global Emerging Technology and Life Sciences Practice. His practice focuses on representing emerging growth companies in the technology and life sciences sectors. He has nurtured startup companies such as CDnow, VerticalNet, ICG Commerce, AirClic, ExcelleRx, and Using the firm's vast resources, he coordinates all aspects of the representation of such companies and concentrates his practice on legal aspects of corporate finance and acquisitions.  Before joining the firm, Mr. Goodman was a senior partner at Wolf Block, Schorr & Solis-Cohen. While there, he served as chairman of the Corporate Law Department, chairman of the Hiring Committee, as a member of the Executive Committee and as chairman of the Venture Development Group.

Jeffrey P. Libson, Legal Council,  Licensing and Partnerships
Jeff Libson is a Corporate and Securities partner in the Berwyn office of Pepper Hamilton LLP. He is the head of the firm’s life sciences practice. Mr. Libson’s practice is devoted primarily to the areas of securities law, venture financing, mergers and acquisitions, corporate governance and the commercialization, licensing and acquisition of intellectual property.  He represents a number of publicly traded and closely held life science companies in ongoing representations as outside general counsel. He also represents a number of non-profit entities that support the life sciences industry.  Within the intellectual property practice area, Mr. Libson has represented numerous companies, including pharmaceutical companies, biotechnology companies, consumer products companies, computer software developers and R&D contractors, in corporate partnering transactions, the acquisition and licensing of patents, trademarks, copyrights and trade secrets, and in the development of new products and technologies.